Black Bird Biotech, Inc. (BBBT)
For informational purposes only. Not financial advice. Analysis by Sedat Aydin, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
Black Bird Biotech, Inc. (BBBT) with AI Score 44/100 (Weak). Black Bird Biotech, Inc. operates in the biotech sector, focusing on biopesticides and CBD products. Market cap: 0, Sector: Healthcare.
Last analyzed: Mar 17, 2026Black Bird Biotech, Inc. (BBBT) Healthcare & Pipeline Overview
Black Bird Biotech, Inc. is a biotech company specializing in plant-based biopesticides and CBD products, including MiteXstream for spider mite eradication and the Grizzly Creek Naturals line of CBD oils and personal care items. The company also engages in industrial hemp cultivation under the Montana Hemp pilot program.
Investment Thesis
Black Bird Biotech, Inc. presents a high-risk, high-reward investment opportunity given its early stage and OTC market listing. The company's focus on MiteXstream, a plant-based biopesticide, addresses a growing demand for sustainable agricultural solutions. However, the company's negative profit margin of -2009.1% and gross margin of -67.7% indicate significant financial challenges. Future growth hinges on successful market penetration of MiteXstream and expansion of the Grizzly Creek Naturals CBD product line. The company's small size and limited resources, managing with only 4 employees, pose operational risks. Investors should closely monitor revenue growth, cost management, and regulatory developments in the biopesticide and CBD markets. The company's beta of 2.01 suggests high volatility.
Based on FMP financials and quantitative analysis
Key Highlights
- Market Cap of $0.00B indicates a micro-cap company with limited financial resources.
- P/E Ratio of -0.02 reflects negative earnings and challenges in achieving profitability.
- Profit Margin of -2009.1% highlights significant losses relative to revenue.
- Gross Margin of -67.7% suggests that the cost of goods sold exceeds revenue, indicating pricing or production inefficiencies.
- Beta of 2.01 indicates higher volatility compared to the market, suggesting a riskier investment.
Competitors & Peers
Strengths
- Proprietary plant-based biopesticide (MiteXstream).
- Established CBD brand (Grizzly Creek Naturals).
- Participation in Montana Hemp pilot program.
- Focus on sustainable and environmentally friendly products.
Weaknesses
- Negative profit and gross margins.
- Limited financial resources.
- Small number of employees (4).
- OTC market listing.
Catalysts
- Upcoming: Potential regulatory approvals for new biopesticide or CBD products.
- Ongoing: Expansion of distribution channels for MiteXstream and Grizzly Creek Naturals.
- Ongoing: Increasing consumer demand for sustainable agricultural solutions and CBD products.
Risks
- Potential: Competition from larger companies with greater resources.
- Potential: Regulatory changes in the biopesticide and CBD markets.
- Ongoing: Negative profit and gross margins.
- Ongoing: Limited financial resources.
- Ongoing: OTC market listing.
Growth Opportunities
- Expansion of MiteXstream Market: The market for biopesticides is projected to grow as environmental regulations tighten and consumer demand for organic produce increases. Black Bird Biotech can capitalize on this trend by expanding the distribution of MiteXstream to new geographic markets and crops. The company can also invest in research and development to improve the efficacy of MiteXstream and develop new biopesticide products. The global biopesticides market is estimated to reach billions of dollars, providing a significant growth opportunity for Black Bird Biotech.
- Growth of Grizzly Creek Naturals CBD Product Line: The CBD market is experiencing rapid growth, driven by increasing consumer awareness of the potential health benefits of CBD. Black Bird Biotech can expand its Grizzly Creek Naturals product line by introducing new CBD-infused products, such as topicals, edibles, and beverages. The company can also expand its distribution channels by partnering with retailers and online marketplaces. The global CBD market is projected to reach billions of dollars, offering a substantial growth opportunity for Black Bird Biotech.
- Strategic Partnerships: Black Bird Biotech can pursue strategic partnerships with agricultural companies, retailers, and other businesses to expand its market reach and product offerings. For example, the company could partner with an agricultural company to distribute MiteXstream to its customers or with a retailer to sell Grizzly Creek Naturals products in its stores. Strategic partnerships can provide Black Bird Biotech with access to new markets, customers, and resources.
- Industrial Hemp Cultivation Expansion: Black Bird Biotech's participation in the Montana Hemp pilot program provides an opportunity to expand its industrial hemp cultivation operations. Industrial hemp can be used to produce a variety of products, including textiles, building materials, and biofuels. Black Bird Biotech can increase its revenue by growing and selling industrial hemp to manufacturers. The market for industrial hemp is growing, driven by increasing demand for sustainable and environmentally friendly products.
- Regulatory Approvals for New Products: Obtaining regulatory approvals for new biopesticide and CBD products can provide Black Bird Biotech with a competitive advantage. Regulatory approvals can demonstrate the safety and efficacy of the company's products, making them more attractive to customers. Black Bird Biotech can invest in research and development to develop new products that meet regulatory requirements. Successfully navigating the regulatory landscape can open doors to new markets and revenue streams.
Opportunities
- Expanding biopesticide market.
- Growing CBD market.
- Strategic partnerships.
- Industrial hemp cultivation expansion.
Threats
- Competition from larger companies.
- Regulatory changes in the biopesticide and CBD markets.
- Fluctuations in commodity prices (hemp).
- Economic downturn affecting consumer spending.
Competitive Advantages
- Proprietary plant-based biopesticide formulation for MiteXstream.
- Established brand recognition for Grizzly Creek Naturals in the CBD market.
- Participation in the Montana Hemp pilot program providing access to hemp cultivation.
- Focus on sustainable and environmentally friendly products appealing to conscious consumers.
About BBBT
Black Bird Biotech, Inc., formerly known as Digital Development Partners, Inc., was rebranded in June 2021 to reflect its focus on biotechnology. The company develops, manufactures, and distributes a range of products, including MiteXstream, a plant-based biopesticide designed to eradicate spider mites, a common pest in agriculture and horticulture. This product represents a key offering in the company's portfolio, targeting the agricultural sector's need for environmentally friendly pest control solutions. In addition to its biopesticide products, Black Bird Biotech also manufactures and sells CBD-infused products under the Grizzly Creek Naturals brand. This line includes CBD oils, gummies, pet treats, and personal care products, catering to the growing market for CBD-based wellness solutions. The company also produces hand sanitizer gel and spray products. Furthermore, Black Bird Biotech participates in the Montana Hemp pilot program, growing industrial hemp for various applications. Based in Flower Mound, Texas, the company aims to leverage its biotech expertise to develop and market innovative products in both the agricultural and consumer wellness sectors. The company's evolution reflects a strategic shift towards biotechnology and a commitment to developing plant-based solutions.
What They Do
- Manufactures and distributes MiteXstream, a plant-based biopesticide.
- Sells CBD oils, gummies, and pet treats under the Grizzly Creek Naturals brand.
- Offers CBD-infused personal care products.
- Produces hand sanitizer gel and spray products.
- Grows industrial hemp under the Montana Hemp pilot program.
- Develops biotech products for agricultural and consumer markets.
Business Model
- Revenue from the sale of MiteXstream biopesticide to agricultural customers.
- Sales of Grizzly Creek Naturals CBD products through retail and online channels.
- Income from the cultivation and sale of industrial hemp.
- Potential revenue from licensing or partnering on its biotech products.
Industry Context
Black Bird Biotech operates within the specialty and generic drug manufacturing industry, which is experiencing growth driven by increasing demand for biopesticides and CBD products. The market for biopesticides is expanding as farmers seek sustainable alternatives to traditional chemical pesticides. The CBD market is also growing, fueled by increasing consumer awareness of the potential health benefits of CBD. However, the industry is highly competitive, with established players and new entrants vying for market share. Black Bird Biotech faces competition from larger companies with greater resources and established distribution networks. The company's success depends on its ability to differentiate its products and effectively market them to target customers.
Key Customers
- Farmers and agricultural businesses seeking biopesticide solutions.
- Consumers interested in CBD-based wellness products.
- Retailers and distributors of agricultural and consumer products.
- Manufacturers who use industrial hemp as a raw material.
Financials
Chart & Info
Black Bird Biotech, Inc. (BBBT) stock price: Price data unavailable
Latest News
No recent news available for BBBT.
Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for BBBT.
Price Targets
Wall Street price target analysis for BBBT.
MoonshotScore
What does this score mean?
The MoonshotScore rates BBBT's growth potential on a scale of 0-100 across multiple factors including innovation, market disruption, financial health, and momentum.
Leadership: Nelson Grist
CEO
Nelson Grist serves as the CEO of Black Bird Biotech, Inc., leading a small team of 4 employees. Information regarding his prior experience and educational background is not available. As CEO, he is responsible for overseeing the company's strategic direction, product development, and sales and marketing efforts. His leadership is critical to the company's success in the competitive biopesticide and CBD markets. Given the limited size of the company, he likely plays a hands-on role in all aspects of the business.
Track Record: Due to the limited information available, it is difficult to assess Nelson Grist's track record at Black Bird Biotech. The company's recent rebranding and focus on biotechnology suggest a strategic shift under his leadership. However, the company's negative profit and gross margins indicate significant challenges in achieving profitability. His success will depend on his ability to effectively manage costs, drive revenue growth, and navigate the regulatory landscape.
BBBT OTC Market Information
The OTC Other tier represents the lowest tier of the OTC market, indicating that Black Bird Biotech may not meet the minimum financial standards or reporting requirements for higher tiers like OTCQX or OTCQB. Companies in this tier may have limited financial disclosure, making it more difficult for investors to assess their financial health and performance. Investing in companies on the OTC Other tier carries a higher degree of risk compared to companies listed on major exchanges like the NYSE or NASDAQ, due to the potential for less transparency and regulatory oversight.
- OTC Tier: OTC Other
- Disclosure Status: Unknown
- Limited financial disclosure.
- Low liquidity and high price volatility.
- Potential for fraud or manipulation.
- Lack of regulatory oversight.
- Going concern risk.
- Verify the company's registration and legal status.
- Obtain and review available financial statements.
- Assess the company's business model and competitive landscape.
- Evaluate the management team's experience and track record.
- Understand the company's capital structure and potential dilution.
- Research any legal or regulatory issues.
- Consult with a financial advisor.
- Existence of a physical address and contact information.
- Presence of a functional website.
- Publicly available press releases and investor information.
- Independent third-party verification of products or services.
- Active participation in industry events or associations.
BBBT Healthcare Stock FAQ
What does Black Bird Biotech, Inc. do?
Black Bird Biotech, Inc. is a biotech company focused on developing and marketing plant-based solutions for the agricultural and consumer wellness markets. Its primary product is MiteXstream, a biopesticide designed to eradicate spider mites in crops. Additionally, the company manufactures and sells CBD-infused products under the Grizzly Creek Naturals brand, including oils, gummies, and personal care items. Black Bird Biotech also participates in the Montana Hemp pilot program, cultivating industrial hemp. The company aims to provide sustainable and environmentally friendly alternatives to traditional chemical pesticides and wellness products.
What do analysts say about BBBT stock?
As of 2026-03-17, there is no available analyst coverage for Black Bird Biotech, Inc. due to its OTC listing and small market capitalization. Key valuation metrics such as price-to-earnings (P/E) ratio and price-to-sales (P/S) ratio are not meaningful due to the company's negative earnings and limited revenue. Investors should conduct their own thorough research and consider the company's financial challenges, growth opportunities, and risks before making any investment decisions. The company's future performance will depend on its ability to improve profitability and expand its market share.
What are the main risks for BBBT?
Black Bird Biotech, Inc. faces several significant risks, including intense competition from larger companies with greater resources, potential regulatory changes in the biopesticide and CBD markets, and the company's negative profit and gross margins. Its limited financial resources and small number of employees pose operational challenges. The company's OTC market listing also carries risks associated with lower liquidity, higher volatility, and limited financial disclosure. Investors should carefully consider these risks before investing in Black Bird Biotech, Inc.
What are the key factors to evaluate for BBBT?
Black Bird Biotech, Inc. (BBBT) currently holds an AI score of 44/100, indicating low score. Key strength: Proprietary plant-based biopesticide (MiteXstream).. Primary risk to monitor: Potential: Competition from larger companies with greater resources.. This is not financial advice.
How frequently does BBBT data refresh on this page?
BBBT prices update in real time during U.S. market hours (9:30 AM-4:00 PM ET, weekdays). Fundamentals refresh after quarterly or annual filings. Analyst ratings and AI insights update daily. News is aggregated continuously from financial sources.
What has driven BBBT's recent stock price performance?
Recent price movement in Black Bird Biotech, Inc. (BBBT) can be influenced by earnings results, analyst revisions, sector rotation, and broader market sentiment. Notable catalyst: Proprietary plant-based biopesticide (MiteXstream).. Check the News and Technical Analysis tabs for the latest drivers. Past performance does not predict future results.
Should investors consider BBBT overvalued or undervalued right now?
Determining whether Black Bird Biotech, Inc. (BBBT) is overvalued or undervalued requires examining multiple metrics. Compare valuation ratios (P/E, P/S, EV/EBITDA) against sector peers for a comprehensive view.
What research should beginners do before buying BBBT?
Before investing in Black Bird Biotech, Inc. (BBBT), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) what Wall Street analysts recommend and their price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Information is limited due to the company's OTC listing and lack of analyst coverage.
- Financial data is based on available information and may not be complete.
- Forward-looking statements are subject to risks and uncertainties.